Analyst Ratings for Alnylam Pharmaceuticals (ALNY)
ALNY Rating Summary
ALNY Price Target Summary
- Highest: $580.00 (Goldman Sachs)
- Lowest: $256.00 (Wells Fargo)
- Average: $396.45
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$396.45 (+57.4%)
* Over Last 12-Mos
Rating Score: 6.9 / 10
Percentile Rank: 73%
Avg. $ Target:
$396.45 (+57.4%)
* Over Last 12-Mos
Rating Score: 6.9 / 10
Percentile Rank: 73%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/18/2026 | BMO Capital » Updated 8/31/2026 |
David Lebowitz | New Coverage | Outperform (N/A) |
318.00 (N/A) |
224.60 (251.93) |
12.17% | Details |
| 8/3/2026 | Raymond James | Martin Auster | Upgrade | Strong Buy (Outperform) |
420.00 (N/A) |
205.52 (251.93) |
22.58% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
